polrmt

IMT1B (LDC203974) is an orally administered, specific noncompetitive allosteric inhibitor of mitochondrial RNA polymerase (POLRMT), effectively suppressing mitochondrial DNA (mtDNA) expression and conferring anti-tumor properties.

IMT1 (Propanamide, N,N-dimethyl-2-[[4-(2-methylphenyl)-2-oxo-2H-1-benzopyran-7-yl]oxy]-) has anticancer activity.

POLRMT-IN-2 is a potent inhibitor of POLRMT, exhibiting significant antiproliferative activity in MOLM-13 cells with an IC50 of 1.01 μM. It disrupts mitochondrial function and induces apoptosis, making it a valuable candidate for research in acute myeloid leukemia (AML).

POLRMT-IN-1 (compound S7) is an inhibitor of POLRMT, specifically utilized in cancer-related research.

YH-0623 is an orally active inhibitor of mitochondrial RNA polymerase (POLRMT) with an IC50 of 50.48 nM as determined by NanoBRET assay. It exhibits antiproliferative effects on 22Rv1 cells by downregulating mitochondrial gene expression. YH-0623 suppresses 22Rv1 cell growth, colony formation, and expression of proteins related to OXPHOS. Significant tumor growth inhibition was observed in a prostate cancer xenograft mouse model. YH-0623 is applicable for prostate cancer research.